1. Search Result
Search Result
Results for "

Fibrin

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

1

Screening Libraries

5

Biochemical Assay Reagents

15

Peptides

3

Natural
Products

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0665

    Others Cardiovascular Disease Cancer
    Fibrin, isolated from bovine blood, is an insoluble protein produced in response to bleeding. Fibrin is the major component of the blood clot and is used for coagulation .
    Fibrin
  • HY-108883

    Fibrinolysins, Human plasma; Serum tryptase, Human plasma; TAL 05-00018, Human plasma

    Others Inflammation/Immunology
    Plasmin, Human plasma is an important protease present in blood that degrades many plasma proteins, including fibrin clots. Plasmin can also act as a potent regulator of the immune process and can directly interact with various cell types, including monocytes, macrophages, and dendritic cells .
    Plasmin, Human plasma
  • HY-125864

    Interleukin Related NF-κB Inflammation/Immunology
    Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .
    Fibrinogen (Bovine)
  • HY-P0074
    GPRP
    1 Publications Verification

    Gly-Pro-Arg-Pro; Pefa 6003

    Integrin Cardiovascular Disease
    GPRP (Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa) .
    GPRP
  • HY-P0074A
    GPRP acetate
    1 Publications Verification

    Gly-Pro-Arg-Pro acetate; Pefa 6003 acetate

    Integrin Cardiovascular Disease
    GPRP acetate (Gly-Pro-Arg-Pro acetate) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa) .
    GPRP acetate
  • HY-B1560
    Bismuth subgallate
    1 Publications Verification

    Factor Xa Others
    Bismuth subgallate, a hemostatic agent, acts on coagulation factor XII (Hageman factor), leading to the activation of the coagulation cascade and improving early formation of a fibrin clot .
    Bismuth subgallate
  • HY-P2373
    Nattokinase, Natto fermentation
    1 Publications Verification

    Others Cardiovascular Disease
    Nattokinase, Natto fermentation is a potent fibrinolytic enzyme. Nattokinase can break down blood clots by directly hydrolyzing fibrin and plasmin substrate. Nattokinase can be used for the research of cardiovascular diseases .
    Nattokinase, Natto fermentation
  • HY-106275

    Fibrin-derived peptide Bβ15-42

    Flavivirus Dengue virus Cardiovascular Disease
    FX-06 (Fibrin-derived peptide Bβ15-42) is a fibrin Bbeta chain-derived peptide. FX-06 binds to VE-cadherin and inhibits leukocyte transmigration and initiates VE-cadherin-mediated signaling. FX-06 can be used in the research of ischemia/reperfusion injury, Dengue shock syndrome (DSS) .
    FX-06
  • HY-122542

    PAI-1 Cardiovascular Disease
    PPACK is a plasminogen activator (rt-PA) inhibitor. PPACK can inhibit changes in fibrin degradation products, plasminogen and alpha 2-antiplasmin. PPACK also inhibits the binding of rt-PA to plasma protease inhibitors .
    PPACK
  • HY-122542A

    Pebac; D-Phenylalanyl-prolyl-arginyl Chloromethyl Ketone; D-Phe-Pro-Arg-CH2Cl

    PAI-1 Cardiovascular Disease
    PPACK dihydrochloride is a plasminogen activator (rt-PA) inhibitor. PPACK dihydrochloride can inhibit changes in fibrin degradation products, plasminogen and alpha 2-antiplasmin. PPACK dihydrochloride also inhibits the binding of rt-PA to plasma protease inhibitors .
    PPACK dihydrochloride
  • HY-122542B

    PAI-1 Cardiovascular Disease
    PPACK TFA is a plasminogen activator (rt-PA) inhibitor. PPACK TFA can inhibit changes in fibrin degradation products, plasminogen and alpha 2-antiplasmin. PPACK TFA also inhibits the binding of rt-PA to plasma protease inhibitors .
    PPACK TFA
  • HY-P4721

    Thrombin Cardiovascular Disease
    Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a KD < 100 nM. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is an antithrombotic agent. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) inhibits the thrombin-induced fibrin clot formation with an IC50 value of 0.087 μM .
    Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated)
  • HY-W040030

    Others Metabolic Disease Cancer
    Hematin, an iron-containing porphyrin, inhibits the activity of clotting factors and also fibrin clot lysis through the mechanism of binding to and inactivation of hemostatic proteins . Hematin can be used for the research of acute porphyrias and cancer .
    Hematin
  • HY-E70230

    SAK

    Others Cardiovascular Disease
    Staphylokinase, staphylococcus aureus (SAK) is a fibrin-specific plasminogen activator. Staphylokinase is an efficient, fibrin-selective thrombolytic agent .
    Staphylokinase, staphylococcus aureus
  • HY-114164A

    EC 3.4.21.5; Human Alpha Thrombin

    Thrombin Cardiovascular Disease
    Human α-thrombin is a multifunctional serine protease that plays a pivotal role in the coagulation pathway. Human α-thrombin cleaves fibrinogen and converts it into fibrin. Human α-thrombin can stimulate platelet activation and stabilize fibrin polymers .
    Human α-Thrombin
  • HY-122311

    SMTP-7

    Reactive Oxygen Species Neurological Disease Inflammation/Immunology
    Orniplabin (SMTP-7) is a low-molecular-weight compound that enhances plasminogen–fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase and plasminogen-mediated fibrin degradation. Orniplabin shows potential thrombolytic and anti-inflammatory effects. Orniplabin inhibits ROS .
    Orniplabin
  • HY-E70393C

    Others Others
    Human Factor XIa is a blood coagulation protease. Human Factor XIa activates the Factor IX and Factor V, resulting in the generation of thrombin and fibrin .
    Human Factor XIa
  • HY-107911
    Protamine sulfate
    1 Publications Verification

    Thrombin Metabolic Disease
    Protamine sulfate, polycationic peptide and a antiheparin agent, could neutralize the anticoagulant action of heparin and enhances lipid-mediated gene transfer .
    Protamine sulfate
  • HY-N1400

    Others Cancer
    (20R)-Ginsenoside Rh1, the R isomer of Ginsenoside Rh1 isolated from Panax Ginseng, inhibits the thrombin-induced conversion of fibrinogen to fibrin .
    (20R)-Ginsenoside Rh1
  • HY-D1480

    Fluorescent Dye Others
    Crystal Ponceau 6R is a red azo dye. Crystal Ponceau 6R used in histology, for staining fibrin with the martius, scarlet and blue (MSB) Trichrome stain .
    Crystal Ponceau 6R
  • HY-P3160
    Fibronectin
    2 Publications Verification

    Integrin Cardiovascular Disease Inflammation/Immunology
    Fibronectin, a glycoprotein present in blood as well as in cells, is a biomarker of tissue injury. Fibronectin binds to membrane-spanning receptor proteins called integrins. Fibronectin also binds to other extracellular matrix proteins such as collagen, fibrin, and heparan sulfate proteoglycans .
    Fibronectin
  • HY-76971

    Factor Xa Cardiovascular Disease
    Dechloro Rivaroxaban is a highly selective, orally active inhibitor of Factor Xa. Dechloro Rivaroxaban inhibits human free FXa with a Ki of 0.4 nM. Dechloro Rivaroxaban inhibits prothrombinase activity and fibrin-associated FXa activity with IC50s of 2.1 nM and 92 nM, respectively .
    Dechloro Rivaroxaban
  • HY-107966

    Nadroparin calcium (MW 15000-19000)

    Thrombin Factor Xa Autophagy Bacterial Cardiovascular Disease Cancer
    Heparin calcium (MW 15000-19000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .
    Heparin calcium (MW 15000-19000)
  • HY-107966A

    Nadroparin calcium (MW 3600-5000)

    Thrombin Factor Xa Autophagy Bacterial Cardiovascular Disease Cancer
    Heparin (Nadroparin) calcium (MW 3600-5000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .
    Heparin calcium (MW 3600-5000)
  • HY-12586

    Others Others
    AZD6564 is an orally active inhibitor for fibrinolysis through disruption of plasma kinase-fibrin interaction. AZD6564 dissolves human plasma clot with an IC50 of 0.44 μM. AZD6564 ameliorates hemorrhage in rats with EC50 of 1.62 μM, and exhibits good pharmacokinetic characteristics in rats .
    AZD6564
  • HY-E70393

    Factor VIIa Others
    Human Factor VIIa is a vitamin K-dependent serine protease that is involved in the blood coagulation process. Human Factor VIIa activates Factor X, which causes the conversion of prothrombin to thrombin and the conversion of fibrinogen to fibrin, leading to the formation of blood clots. Human Factor VIIa exhibits the potential to ameliorate Hemophilia .
    Human Factor VIIa
  • HY-123120

    Others Others
    SA-152 is an organophosphorus inhibitor. SA-152 modulates the fibrinogen coagulation and TAME esterase activity of bovine α-thrombin .
    SA-152
  • HY-124499

    Integrin Cardiovascular Disease
    RUC-1 (Compound 1) is an inhibitor for αIIbβ3 integrin. RUC-1 inhibits fibrin deposition and platelet aggregation in hybrid hαIIb/mβ3 receptors expressing mice. RUC-1 exhibits antithrombotic effect in hαIIb/mβ3 receptor expressing mice .
    RUC-1
  • HY-P2821

    Others Inflammation/Immunology
    Plasminogen, Human plasma is a secreted protein that upon cleavage by urokinase plasminogen activator (uPA) or tissue plasminogen activator (tPA) is converted to plasmin, a broad range protease capable of cleaving fibrin and other ECM components. Plasminogen also is a proinflammatory regulator that accelerates the healing of acute and diabetic wounds. Plasminogen can be used in studies of wound healing, inflammation and hypoplasminogenemia .
    Plasminogen, Human plasma
  • HY-114164C

    Protease Activated Receptor (PAR) Inflammation/Immunology
    Thrombin, Pig blood is a key enzyme in the coagulation cascade, responsible for converting fibrinogen into fibrin. Thrombin, Pig blood activates platelet activation, endothelial cell function, and inflammatory responses by binding to PAR-1 and PAR-4, which triggers G protein-coupled signaling pathways. Thrombin, Pig blood holds promise for research in coagulation and inflammation fields .
    Thrombin, Pig blood
  • HY-10275

    AR-H067637

    Thrombin Cardiovascular Disease
    Atecegatran (AR-H067637) is an orally active competitive thrombin inhibitor with a Ki of 2-4 nM. AR-H067637 inhibits platelet activation and aggregation by blocking thrombin binding to fibrin and thrombomodulin. Atecegatran demonstrates significant anticoagulant effects in various plasma coagulation assays, with an IC50 ranging from 93 to 220 nM. Atecegatran can be used in research related to thromboembolic disorders .
    Atecegatran
  • HY-B1064
    Clindamycin phosphate
    5+ Cited Publications

    Clindamycin 2-phosphate; U-28508

    Bacterial Antibiotic Parasite Infection
    Clindamycin phosphate (Clindamycin 2-phosphate) is a broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin phosphate is the proagent of Clindamycin (HY-B1455) with no antimicrobial activity in vitro but can be rapidly converted in vivo to the active parent agent, Clindamycin, by phosphatase ester hydrolysis. Clindamycin phosphate can be used for researching acne and bacterial vaginosis .Clindamycin phosphate has no cytotoxicity。 Combined with platelet rich fibrin (PRF), PRF-Clindamycin phosphate enhances antimicrobial properties .
    Clindamycin phosphate
  • HY-W854721

    Manganese(III) Protoporphyrin IX Chloride

    Others Metabolic Disease
    Mn(III) protoporphyrin IX chloride is a metalloporphyrin. It induces mRNA expression of the genes encoding δ-aminolevulinate synthase and heme oxygenase (HO), enzymes that catalyze the rate-limiting steps of heme biosynthesis and degradation, respectively, in chick embryo liver cells when used at a concentration of 10 μM. Mn(III) protoporphyrin IX chloride-containing nanobialys have been used in magnetic resonance imaging (MRI) of fibrin clots in vitro. It has also been used in the synthesis of Mn(III) protoporphyrin IX-6(7)-glycyl-glycyl-L-histidine methyl ester (MnGGH), a metalloporphyrin conjugate with microperoxidase activity.
    Mn(III) Protoporphyrin IX chloride
  • HY-16268
    Kartogenin
    Maximum Cited Publications
    23 Publications Verification

    KGN

    TGF-beta/Smad Inflammation/Immunology
    Kartogenin (KGN) is an inducer of chondrogenic tissue formation (EC50: 100 nM). Kartogenin induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .
    Kartogenin
  • HY-16268A
    Kartogenin sodium
    Maximum Cited Publications
    23 Publications Verification

    KGN sodium

    TGF-beta/Smad Inflammation/Immunology
    Kartogenin (KGN) sodium is an inducer of chondrogenic tissue formation (EC50: 100 nM). Kartogenin sodium induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin sodium also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin sodium is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin sodium promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .
    Kartogenin sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: